Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  temozolomide
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 155 for your search:
Start Over
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00616, CALGB-A071102, A071102, U10CA180821, U10CA031946, NCT02152982
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: Tg 511-15-01, NCT02414165
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TASMC-05-FB-05235-CTIL, NCT00268684
Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000582632, EORTC-26053, CAN-NCIC-CEC1, RTOG-0834, EORTC-22054, EUDRACT-2006-001533-17, SPRI-EORTC-26053, MERCK-EORTC-26053, MRC-BR14, COGNO-EORTC-26053, CEC1, NCT00626990
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000654697, ECOG-E3F05, E3F05, NCT00978458
Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08 TETE 01, NCT01507506
Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2012012, NCT01649830
A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CSNO2012001, NCT01765088
Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P120105, 2012-004536-34, NCT01805453
PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PV-10-MM-31, NCT02288897
Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 60 and over
Sponsor: Other
Protocol IDs: P130950, 2014-002597-37, NCT02313389
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Eudract-2005-003911-63, PEI 119/01, NCT00311857
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 021-003, NCT00394628
Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2000.00, NCI-2013-00701, 8357, P30CA015704, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 200807728, NCT00925132
PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRN0012, SU-04202010-5726, 17774, NCT01120639
Vitamin D for Treatment of Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SOR504110CTIL, NCT01181193
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2011-0073, NCI-2011-02768, NCT01409174
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-00082, 12-C-0213, CDR0000717423, P12978, PBTC-033, U01CA081457, NCT01514201
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 11I03, NCI-2011-02939, STU00053541, NCT01465659
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12414, 2011-006140-78, U1111-1124-1403, NCT01587040
Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MEVITEM, 2011-003372-37, NCT01601184
Study of MLN8237 in Combination With Irinotecan and Temozolomide
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 30
Sponsor: Other
Protocol IDs: N2009-03, NCT01601535
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PLX108-08, NCT01790503
Start Over